ICON plc: ICON Reports Third Quarter 2026 Results
ICON plc reported Q3 2026 results with revenue of $2.02B, adjusted EBITDA of $336.9M, and net income of $122.1M. The company had net business wins of $3.15B and a book-to-bill ratio of 1.56x. ICON repurchased $400M in stock and updated its 2026 guidance, expecting revenue between $8.1B and $8.2B and adjusted EPS between $10.35 and $10.65.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh guidance and a sizable share buyback, offering a clear catalyst for short‑term trading.
Market read
First‑time disclosure of earnings and guidance creates a material trading opportunity.
What to watch
High share repurchase activity may limit cash for growth initiatives.
Background
ICON plc is a Dublin‑based clinical research organization listed on NASDAQ.
Ticker impact
Q3 2026 earnings and updated full-year guidance were disclosed for the first time.
likely modest upside as market prices in higher full-year revenue and EPS guidance
The company reported a $2.0B revenue, adjusted EBITDA of $336.9M and raised FY2026 revenue guidance to $8.1-$8.2B, providing fresh positive material.
Market effects
Strong results may boost sentiment in the clinical research services sector.
Positive for European biotech and CRO stocks.
Limited to investors tracking CRO earnings and guidance.
Counterpoint
Revenue decline and lower margins could signal underlying demand weakness.
Key entities
- companyICON plc
Clinical research organization reporting Q3 2026 results.


